Dexmedetomidine infusion effect on post-operative delirium

The effect of Dexmedetomidine infusion on post-operative delirium (POD) in patients on pump coronary artery bypass grafting (CABG)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250512065695N1

Enrollment

100

Registered

2025-05-16

Start date

2025-05-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

on-pump coronary artery bypass graft surgery. Presence of aortocoronary bypass graft

Interventions

Intervention 1: Intervention group: Intravenous infusion of dexmedetomidine after the induction of anesthesia, starting at a dose of 0.6 micrograms per kilogram per hour, and continued until the end o

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients scheduled for on-pump coronary artery bypass grafting (CABG) Informed consent Patients with sufficient cognitive function to participate in the study (assessed by MMSE) Psychological status: Patients with acceptable levels of depression and anxiety (assessed by PHQ-4) Absence of preoperative delirium: Patients without signs of delirium before surgery No severe hepatic or renal failure

Exclusion criteria

Exclusion criteria: Concurrent valve replacement surgery along with CABG Emergency CABG surgery Known allergy or hypersensitivity to dexmedetomidine Patients in a coma or intubated prior to surgery Patients with moderate to severe hearing impairment or deafness Bradycardia (heart rate <60 bpm) at the time of anesthesia induction Hypotension (systolic blood pressure <100 mmHg) at the time of anesthesia induction Need for reoperation within the first postoperative day Withdrawal of patient consent at any stage during hospitalization

Design outcomes

Primary

Measure	Time frame
Determining the incidence of confusion and delirium in intervention and control groups. Timepoint: In the first and second days after surgery in the cardiac ICU, daily assessments will be conducted during each shift. Method of measurement: Neelon & Champagne Confusion Scale.;Determining the incidence of delirium in intervention and control groups. Timepoint: In the first and second days after surgery in the cardiac ICU, daily assessments will be conducted during each shift. Method of measurement: CAM-ICU Scale.	—

Measure

Time frame

Determining the incidence of confusion and delirium in intervention and control groups. Timepoint: In the first and second days after surgery in the cardiac ICU, daily assessments will be conducted during each shift. Method of measurement: Neelon & Champagne Confusion Scale.;Determining the incidence of delirium in intervention and control groups. Timepoint: In the first and second days after surgery in the cardiac ICU, daily assessments will be conducted during each shift. Method of measurement: CAM-ICU Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShiva Rezaeian

Mashhad University of Medical Sciences

shivarezaeian7388@gmail.com+98 51 3604 6080

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026